Medical researchers are steps from legalizing ecstasy. Here’s how they did it.

“Regulators, governments, health economists, health systems, insurers, health-care professionals, and—most importantly—patients,” said George Goldsmith, the former CEO of McKinsey & Company’s TomorrowLab, and an advocate for the kind of therapeutic innovation psychedelic researchers are hoping to achieve. “That’s the next community that actually needs to be engaged here.”

For Doblin, it represents a life’s effort, and a conscious decision as a young man to work within the system rather than against it. “I saw early on the value of scientific research and fully believed in the idea of working through the FDA’s clinical research procedures to obtain approval for prescription use,” he says. “I’d seen the backlash against the ’60s and realized that incremental change, evolutionary rather than revolutionary, was going to be required. I just didn’t realize I’d still be working towards the medicalization of psychedelics 45 years later!” “Ask your best questions,” Doblin told the attendees at Psychedelic Science 2017. “Be really responsive to the fears and anxieties of the larger culture, and let’s see how we can address them. Bring your best, most critical, but open-minded, open-hearted selves to bear on the conference.” “If we do that,” he said, smiling like his 18-year-old self, “this can become more than a dream.”

Original Article (Reason):
Medical Researchers Are Steps From Legalizing Ecstasy. Here’s How They Did It.
Artwork Fair Use: Anna Mikhasyuk


…for macrodosing

Leave a Reply